Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UHRF1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
UHRF1 siRNA is a research-stage small interfering RNA (siRNA) designed to silence the expression of Ubiquitin-like containing PHD and RING finger domains 1 (UHRF1), a critical epigenetic regulator. UHRF1 is essential for maintaining DNA methylation patterns by recruiting DNA methyltransferase 1 (DNMT1) to hemimethylated DNA and regulating histone deacetylation. By knocking down UHRF1, this RNA interference (RNAi) agent can induce cell cycle arrest, promote apoptosis, and reactivate silenced tumor suppressor genes. Preclinical studies have explored its potential in treating various cancers, including bladder cancer, cervical squamous cell carcinoma, and pre-B-cell acute lymphoblastic leukemia, as well as fibrotic diseases like pulmonary fibrosis, where it may arrest fibroblast proliferation. It is primarily used as a laboratory tool and has not yet entered clinical development as a proprietary therapeutic asset.
- Other names
- siRNA-UHRF1siRNA-UHRF-1siRNA-UHRF 1UHRF1 small interfering RNAUHRF-1 small interfering RNAUHRF 1 small interfering RNA
02
Targets
UHRF1
Beyond the preview
Go deeper on UHRF1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UHRF1 siRNA.